Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

Ruben Mesa

Review of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Cleveland Clinic Taussig Cancer Institute

A. Gerds

2024 Updates on Myelofibrosis and Systemic Mastocytosis

Indy Hematology Review

R. Rampal

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Implicat…

Insights from 2023 ASH Annual Meeting

D. Tremblay

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

R. Mesa

Key Updates in AML, MDS, & MF From ASH

Memorial Sloan Kettering Cancer Center

A. Goldberg

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

Current and Future Treatment Landscape of Myelofibrosis

XV Eurasian Hematology-Oncology Congress - EHOC 2024

R. Komrokji

2024 Updates in Myeloproliferative Neoplasms

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

E. Hexner

Management of MF After Ruxolitinib Failure

Vanderbilt University Medical Center (VUMC)

A. Kishtagari

Counseling Patients With Newly Diagnosed PV or ET

Krisstina Gowin

Current Treatment Landscape of JAK Inhibitors in MF

Moffitt Cancer Center

A. Kuykendall

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…

Indy Hematology Review

A. Tefferi